WDFY2 and cancer: WDFY2 appears to be deleted in many cancer types from different origins (blue columns in Supplementary Figure S3B,C), with the highest frequency in prostate (>5% in most of the studies) and bladder cancers (3–4% of the cases by selecting the individual studies with more than 100 patients).